Sign in Subscribe
Genetic research

Genetic Ancestry Plays Crucial Role in Personalized Medicine for Aggressive Cancer Treatment

Strategic Insights

— 1 min read

Children's Hospital of Philadelphia (CHOP) investigators have made a groundbreaking discovery about the impact of genetic ancestry on the treatment of a specific and aggressive cancer, T-cell acute lymphoblastic leukemia (T-ALL). The collaborative study published in the journal Blood Cancer Discovery has reinforced the importance of personalized medicine in advancing cancer treatment for pediatric patients. The research highlights the need for tailored approaches based on individual genetic profiles, rather than relying solely on traditional European-centered data. This study suggests that failure to account for genetic ancestry may lead to undertreatment or overtreatment of patients from non-European backgrounds, particularly those of African ancestry.

Key Takeaways:

  • The study found that genetic ancestry affects the impact of certain gene changes in T-ALL, with 80% of patients having mutations in genes where prognostic impact varied depending on their genetic ancestry.
  • Researchers analyzed complete sequencing for 1,309 individuals with T-ALL, including patients of European, African, and other ancestries.
  • A gene called NOTCH1 was linked to better survival in patients of European ancestry but was not associated with better survival in patients of African ancestry.
  • One method for grouping patients into risk categories worked well regardless of ancestry, but another tool developed from European data sometimes gave misleading results for people from non-European backgrounds.
  • The study emphasizes that certain genetic ancestries may be associated with more aggressive disease forms or different responses to treatment.
  • The researchers recommend investigating these findings in other types of cancer to improve outcomes for patients of all ancestral backgrounds.

Statistics:

  • 80% of patients with T-ALL had mutations in genes where prognostic impact varied depending on their genetic ancestry.
  • 1,309 individuals with T-ALL were included in the study.
  • Patients from non-European backgrounds accounted for a significant portion of the study participants.
  • 200,000 children worldwide are diagnosed with cancer each year.

Sources:

  • Newman et al. "Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia." Blood Cancer Discov. Online May 28, 2025. DOI: 10.1158/2643-3230.BCD-25-0049.
  • "Our research demonstrates it is essential to ensure the equitable implementation of genomic biomarkers in treatment decisions or we may introduce disparities," said David T. Teachey, MD, a lead study author at CHOP and Chair of the Acute Lymphoblastic Leukemia Disease Committee in the COG.

Read more